Skip to content
OpenCapital
Get started

BioSig Technologies, Inc. STEX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Bit Digital logo
Bit DigitalBTBT
$105.15M+1,021%
Scilex Holding Company logo
Scilex Holding CompanySCLX
$9.14M+396%
StoneX Group Inc. logo
StoneX Group Inc.SNEX
-$299.8M-259%
Medtronic logo
MedtronicMDT
——
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
——

Other financials

Income statement

See full
Revenue$13.0K+8.3%
Gross profit$12.0K-88.9%
Operating income-$35.7M-1,098%
Net income-$46.7M-1,560%
EPS (diluted)-$0.27-92.9%

Balance sheet

See full
Cash & equivalents$6.9M+84.0%
Total debt$15.0K-94.7%
Total equity$159.0M+6,003%
Total assets$173.3M+3,823%

Cash flow

See full
Operating cash flow-$10.2M-813%
CapEx$4.0K-93.1%
Free cash flow-$2.9M+29.4%

Valuation

See full
Market cap$88.66M-61.8%
P/S2,216.6×-5,967×

Profitability

See full
Gross margin80.1%+25.2pp
Operating margin-32,155%-14,261pp
Net margin-25,825%-11,789pp
FCF margin-97,216.7%-106,293pp

Returns & leverage

See full
Return on equity-627.1%—
Debt / equity0×—
Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioSig Technologies, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
BioSig Technologies, Inc. (STEX) reported cash provided by (used in) financing activity, including discontinued operation of -$1.64M in Q1 2026.
How has BioSig Technologies, Inc.'s cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
BioSig Technologies, Inc.'s cash provided by (used in) financing activity, including discontinued operation decreased by 134.8% year-over-year, from $4.7M to -$1.64M.
What is the long-term trend for BioSig Technologies, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
Over 3 years (2022 to 2025), BioSig Technologies, Inc.'s cash provided by (used in) financing activity, including discontinued operation has grown at a 73.1% compound annual growth rate (CAGR), from $10.57M to $54.88M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.